Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: Progressive shortening in response duration and survival after each relapse Journal Article


Authors: Kumar, A.; Sha, F.; Toure, A.; Dogan, A.; Ni, A.; Batlevi, C. L.; Palomba, M. L. M.; Portlock, C.; Straus, D. J.; Noy, A.; Horwitz, S. M.; Moskowitz, A.; Hamlin, P.; Moskowitz, C. H.; Matasar, M. J.; Zelenetz, A. D.; Younes, A.
Article Title: Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: Progressive shortening in response duration and survival after each relapse
Abstract: As the survival of patients with mantle cell lymphoma (MCL) continues to improve, patients are increasingly being treated with multiple regimens. However, outcome after each line remains poorly characterized in the modern era. To address this knowledge gap, we retrospectively studied 404 consecutive MCL patients who were managed between 2000 and 2014 at Memorial Sloan Kettering Cancer Center. Histologic diagnosis was centrally confirmed, and patients were followed longitudinally from diagnosis throughout their disease course. Progression-free survival (PFS) and overall survival (OS) were determined by Kaplan–Meier method. The median OS and PFS after first-line treatment were 9.7 and 4.0 years, respectively. After second-line therapy, the median OS and PFS were 41.1 and 14.0 months, third line were 25.2 and 6.5 months, and fourth line were 14.4 and 5.0 months. In patients less than 65 years, stem cell transplant (SCT)-based frontline regimens were associated with improved PFS compared with non-SCT regimens (median PFS: 86.2 versus 40.0 months; P < 0.01), with a trend toward longer OS (median OS: 165.0 versus 120.0 months; P = 0.06). Early treatment failure after first-line regimens was associated with worse OS (5.9 versus 2.5 years; P < 0.01). Our study should facilitate establishing proper endpoints for future clinical trials using novel treatment approaches. © 2019, The Author(s).
Journal Title: Blood Cancer Journal
Volume: 9
Issue: 6
ISSN: 2044-5385
Publisher: Nature Publishing Group  
Date Published: 2019-05-20
Start Page: 50
Language: English
DOI: 10.1038/s41408-019-0209-5
PROVIDER: scopus
PMCID: PMC6527702
PUBMED: 31110172
DOI/URL:
Notes: Article -- Export Date: 3 June 2019 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Carol Portlock
    198 Portlock
  2. Craig Moskowitz
    391 Moskowitz
  3. Ariela Noy
    229 Noy
  4. Maria Lia Palomba
    170 Palomba
  5. Steven M Horwitz
    418 Horwitz
  6. Andrew D Zelenetz
    604 Zelenetz
  7. Alison Moskowitz
    184 Moskowitz
  8. Paul Hamlin
    188 Hamlin
  9. Matthew J Matasar
    153 Matasar
  10. David J Straus
    249 Straus
  11. Anita Kumar
    71 Kumar
  12. Connie Wing-Ching Lee
    73 Lee
  13. Anas Younes
    250 Younes
  14. Ahmet Dogan
    238 Dogan
  15. Ahmed   Toure
    7 Toure
  16. Ai   Ni
    84 Ni
  17. Fushen Sha
    5 Sha